Bayer is weighing legal action and Novartis has expressed concern at plans by doctors in the north of England to defy official guidance by using a cancer medicine as a cheap eye drug.
The British government has rekindled its industrial strategy, unveiled earlier in 2017 to prepare the economy for Brexit, with plans to boost the country’s pharmaceuticals sector via fresh investments and public-private collaborations.
A breast cancer drug at the center of a prolonged pricing row in Britain will now be paid for routinely following a discount deal between Roche and the NHS.
Paul Ranson, of global law firm Morgan Lewis’ London Life Science’s Practice, examines how the UK Biopharma must now adapt to a changing landscape.
The digital HCP engagement provider Physicians Interactive announced two major strategic moves in the past two months, acquiring the HCP content platform Univadis from Merck in October and then rebranding itself as Aptus Health in November. Univadis, previously a wholly owned subsidiary of Merck, has an active membership of more than 3 million HCPs in […]
Builds on Current Momentum Towards Broadening Access to This Contraceptive Option for Women Across the Globe September 24, 2015 12:01 AM Eastern Daylight Time NEW YORK–(BUSINESS WIRE)–Pfizer Inc. announced today that the company’s injectable contraceptive, Sayana® Press (medroxyprogesterone acetate), is now available to women in the United Kingdom (UK) for administration by self-injection. […]
McKesson Announces Agreement to Purchase the Pharmaceutical Distribution Division of UDG Healthcare plc • McKesson to acquire the pharmaceutical distribution division of UDG Healthcare plc for €408 million in cash. • Acquisition will add a leader in pharmaceutical distribution across the Republic of Ireland and Northern Ireland to McKesson’s European business. • The acquisition is […]